Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Hepatocellular 9Neoplasm Metastasis 5Stomach Neoplasms 4Biliary Tract Neoplasms 4Neoplasms 3Esophageal Squamous Cell Carcinoma 3Small Cell Lung Carcinoma 2Sarcoma 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Locally Advanced Rectal Cancer 2Hodgkin Disease 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Recurrence 1Plaque, Atherosclerotic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Overall Survival 1Osteosarcoma 1NSCLC 1

Interventions

nimotuzumab 1Sorafenib 1Radiofrequency Ablation 1Immune Checkpoint Inhibitors 1Hematologic Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × HCC × Immune Checkpoint Inhibitors × Clear all
NCT06413017 2024-05-14

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled

HCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡